APLENC LAB

Research in the Aplenc Lab focuses on improving treatment and clinical outcomes for pediatric acute myeloid leukemia (AML) through translational research, patient-centered studies, and large data projects. Current studies include identifying new therapy targets by analyzing the AML blast surface, developing CAR clinical trials for relapsed/refractory AML, and investigating genetic factors contributing to treatment complications via genome-wide genotyping and sequencing.

The lab also conducts patient-centered outcomes research, such as a multi-center study comparing inpatient and outpatient management post-chemotherapy, integrating medical outcomes with interviews and quality of life data. Additionally, clinical epidemiology studies utilize diverse datasets, including Children's Oncolgoy Group (COG) Phase III trial data, Pediatric Health Information Systems (PHIS) billing data, and Center for International Blood and Marrow Transplant Research (CIBMTR) registry data.